Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Objective The aim was to evaluate the efficacy, safety and tolerability of rivastigmine capsules in patients diagnosed with probable vascular dementia (VaD). Methods VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. VaD patients aged 50-85 years were randomized to rivastigmine capsules (3-12 mg/day) or placebo. Efficacy assessments included global and cognitive performances, activities of daily living and neuropsychiatric symptoms. Adverse events were recorded. Additional exploratory analyses determined whether heterogeneity in pathologies and symptoms extended to differential treatment effects. Trial registration NCT00099216. Results 710 patients were randomized. Rivastigmine demonstrated superiority over placebo on three measures of cognitive performance (Vascular Dementia Assessment Scale, Alzheimer's Disease Assessment Scale cognitive subscale, Mini-Mental State Examination; all p or =75 years old), assumed more likely to also have Alzheimer's disease (AD) pathology, demonstrated significant cognitive responses to rivastigmine and a safety profile similar to that seen in AD patients. Younger patients, assumed less likely to have concomitant AD pathology, showed no efficacy response and were associated with slight elevations of blood pressure, cerebrovascular accidents and mortality. Rivastigmine-placebo differences in patients with, versus those without, medial temporal atrophy (also suggestive of concomitant AD) showed a numerical difference similar to that seen between the older versus younger patients, but did not attain statistical significance. Conclusion Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. The efficacy apparent on cognitive outcomes was derived from effects in older patients likely to have concomitant Alzheimer pathology. This is supportive of an existing argument that the putative cholinergic deficit in VaD reflects the presence of concomitant Alzheimer pathology.

What this study adds

Evidence grade: High

This is a trial of 710 participants. The authors read this as support for the idea that any cholinergic deficit in vascular dementia reflects co-existing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C., et al. (2008). Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion. https://doi.org/10.1185/03007990802328142

Vancouver

Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion. 2008. doi:10.1185/03007990802328142. PMID: 18674411.

BibTeX

@article{ballard2008-18674411,
  author  = {Ballard, C. and Sauter, M. and Scheltens, P. and He, Y. and Barkhof, F. and van Straaten, E. C. and van der Flier, W. M. and Hsu, C. and others},
  title   = {{Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study}},
  journal = {Current medical research and opinion},
  year    = {2008},
  doi     = {10.1185/03007990802328142},
  pmid    = {18674411},
  url     = {https://doi.org/10.1185/03007990802328142}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this 24-week trial of 710 people with probable vascular dementia, rivastigmine capsules beat placebo on three cognitive tests but not on other outcomes, and the authors concluded it "did not provide consistent efficacy." The cognitive benefit came from patients aged 75 and older, who the authors assumed were more likely to also have Alzheimer's pathology; younger patients showed no benefit and slight rises in blood pressure, strokes and deaths. The authors read this as support for the idea that any cholinergic deficit in vascular dementia reflects co-existing Alzheimer's disease.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 3 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Current medical research and opinion)
Journal's citation record 1 / 4 Current Medical Research and Opinion: journal h-index 146 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 2 / 4 710 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 5 / 7 Cited 148 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.4 citations a year over 20 year(s) since 2008
Impact for its field and year 3 / 6 Cited 4.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 14 other studies in this library
Still being cited 1 / 4 Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Roger M. Lane: h-index 47 (OpenAlex, whole career)
Institution's track record 1 / 3 King's College London: institution h-index 1,348 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18674411)
Free to read 0 / 2 Behind a paywall — scores zero
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →